T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
PAST TOP PICK

Pfizer Inc(PFE)

Dec 03, 2007
(A Past Top Pick. Dec 5/06. Down 4.8%.) 5% yield is why he still likes it. All of the bad news is basically known. Sold their consumer products division for $19 billion and will use the cash for acquisitions, share buybacks, dividend increases and increase research. Recession resistant.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.55

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Nov 30, 2007
It has all the value characteristics that he loves. Has a lot of net cash. Very cheap. Concerned about administration changes when the US election occurs and that their biggest selling drug Lipitor is about 30% of their sales.
Photo of Pat NaccaratoPat Naccarato
No
Unlock Rating
$23.76

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 20, 2007
(A Top Pick Dec 26/06. Down 12.6%.) Still undervalued. Hopefully there’s pressure on management to do something. His model price is $38.27. a 68.5% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.72

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 20, 2007
(All 3 Top Picks are defensive, have good dividends, solid earnings and limited downside.) 5% yield and will probably raise the dividend. About $19 billion cash for acquisitions. Drugs that are coming off patent is already built into the stock.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$22.72

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 01, 2007
(A Top Pick Dec 21/06. Down 5.6%.) The model price is $42.64, giving it a 73% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.95

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 23, 2007
Has taken it's licks. If they prevail on their lawsuits on their patents then they will go up. He likes the generics more then the big R & D houses.
Photo of David BaskinDavid BaskinUnlock Rating
$23.98

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 16, 2007
Trading at a very attractive multiple (less then 10X next years earnings), 4.5% dividends. They have a lot of things going on in the pipeline. Must be patient with this though.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$24.63

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 10, 2007
His model price is $42.32 a positive 66% differential. Until they read off their goodwill, the stock will probably be in the doghouse for a while.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.54

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 11, 2007
This is a value stock. A number of its drugs have either come off patent or will be in the next 2, 3 years. On the other hand, it has a strong research/development pipeline and about $19 billion in cash. Cash will be used to raise the dividends, buy back
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.19

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 10, 2007
Many pharmaceuticals are faced with an uncertain political environment. This is more important than patent expirations. They are faced with a national health system in the US if there is a change in the government in 2008.
Photo of Alan Kral , CFA, CICAlan Kral , CFA, CIC
No
Unlock Rating
$23.96

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 29, 2007
You are getting almost 5% yield while waiting for their pipeline to improve. All the bad news about drugs coming off of patent is out now. Have a huge cash horde that they will use at the right time to acquire companies with promising drugs.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.67

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2007
His model price is $39.86, a 61% positive differential. In his top 10. The one consolation on this is that you get a 5% dividend while you wait. Hopes they will write off a lot of their Pharmacia acquisition. Until they do, he doesn't expect much movement.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$24.65

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 16, 2007
Almost 5% yield. Their cholesterol drug is coming off patent, which almost made up 25% of their revenues. They have to find a way to replace this.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$23.39

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 15, 2007
Corrected partly because of the market and also its latest earnings report was somewhat disappointing even though the company advised that the full year and next year's earnings are expected to be as they previously stated. Almost 5% yield, which totally limits downside risk in the stock. On a market turn around, this will be a major participant.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.53

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jul 27, 2007
(A Top Pick July 21/06 Up 1%.) Pays a 5% dividend. His model price is $41.35, a 71% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.79

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 556 to 570 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like